论文部分内容阅读
抽取收治的急性脑梗死患者76例,随机均分为两组:对照组行常规治疗,观察组在对照组的基础上取马来酸桂哌齐特治疗,观察两组的临床疗效及NIHSS评分状况。观察组有效34例(89.47%);对照组有效29例(76.32%),观察组有效率明显高于对照组,差异具有统计学意义(P<0.05)。经药物治疗后,观察组的NIHSS评分为(7.35±2.40),对照组为(13.09±3.37),观察组的NIHSS评分低于对照组,差异具有统计学意义(P<0.05)。急性脑梗死患者入院后,在常规治疗的基础上辅以马来酸桂哌齐特治疗,不仅能有效控制疾病发展,还能提高预后生存质量,值得推广使用。
A total of 76 patients with acute cerebral infarction were randomly divided into two groups: the control group received routine treatment, and the observation group received cinepazide maleate on the basis of the control group. The clinical efficacy and NIHSS score situation. The observation group was effective in 34 cases (89.47%); the control group was effective in 29 cases (76.32%), the observation group effective rate was significantly higher than the control group, the difference was statistically significant (P <0.05). After drug treatment, the NIHSS score of the observation group was (7.35 ± 2.40) and that of the control group (13.09 ± 3.37), and the NIHSS score of the observation group was lower than that of the control group (P <0.05). Acute cerebral infarction patients admitted to hospital on the basis of conventional treatment with cinepazide maleate treatment, not only can effectively control the disease development, but also improve the quality of life of the prognosis, it is worth promoting the use of.